Wilbur B. Bowne, MD FACS, FSSO was a Professor of Surgery, Biochemistry and Molecular Biology at Thomas Jefferson University and served as Chief of the Section of Surgical Oncology. His clinical expertise includes treatment of hepatopancreaticobiliary diseases, complex GI cancers, soft tissue sarcoma, and peritoneal surface malignancies that utilizes cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). He has received numerous awards for outstanding service, teaching excellence, operating skills and commitment to the clinical care of patients. Dr. Bowne has considerable expertise in the treatment of peritoneal surface malignancies (PSM) and programmatic growth and development of CRS and HIPEC programs at two large centers in Philadelphia: Drexel University College of Medicine/Hahnemann University Hospital and Thomas Jefferson University. His accomplishments include disease-based translational/outcomes research and clinical trial initiatives moving this important treatment paradigm forward. Most recently, Dr. Bowne’s research team published a worldwide study looking at textbook oncologic outcomes (TOO) for colon cancer with peritoneal metastasis treated with CRS and HIPEC. He is an active member of the Society of Surgical Oncology Peritoneal Surface Malignancy Consortium group and participated in the first and soon published PSM consensus group recommendations for disease sites. Dr. Bowne takes great pride in being a member of multidisciplinary cancer teams that treat the most complex patient situations whatever the circumstance or nature of the condition.